marketing-medtech

**Founder:** Raphaëlle Taub — CEO & Co-founder
**Background:** insurance | verified: True — Raphaëlle Taub's professional background is in physics academia and (re)insurance. She trained in physics/biophysics at ENS Lyon, holds a doctorate in physics (University of Paris-Saclay) and an MBA for scientists from Collège des Ingénieurs. Her first job after her MBA was in reinsurance risk analysis, before she co-founded the femtech/medical-AI startup Matricis.ai (AI for detecting gynecological pathologies such as endometriosis), where she is CEO & Co-founder.
**Stage / fundraise:** Early-stage (founded 2022), deeptech spin-out from ENS/INRIA + AP-HP; first US clinical pilot launched April 2026. / Accelerator/grant-backed (Allianz France, Station F, 212Founders, i-Lab 2024); no confirmed priced round — likely building toward a raise.
**Regulatory trigger:** Class IIa SaMD under EU MDR (CE marking + clinical validation + reimbursement) and now US/FDA path via SimonMed pilot.
**Email:** contact@matricis.ai (confidence high) — Published in the official EndomAI/SimonMed press release as the company contact ("Raphaelle Taub | contact [at] matricis.ai | https://matricis.ai"), via the Yahoo Finance syndication of the GlobeNewswire release (April 2026). This is a real, published address — not inferred.
**LinkedIn:** https://www.linkedin.com/in/raphaelle-taub-370382b9 **Website:** https://matricis.ai/
**Score:** 12 -> Tier A
**Hook:** Open on the SimonMed US pilot + the candid "decade-long diagnostic delay is unacceptable" framing, then connect her reinsurance/risk lens to the regulatory reality: a class IIa SaMD heading into both CE marking and the US needs auditable IEC 62304 traceability and clinical evidence — built once, reused for both files. Position OmDev as the senior dev team + dedicated CTO + compliance engine (SOUP register signed each build, requirements-to-code-to-test traceability feeding the MDR/IEC 62304 file) that lets a lean deeptech ship production-grade medical software ~3x cheaper than hiring it in-house, at a fixed monthly price, with Matricis owning the code — so the team's ML talent stays focused on the model, not on standing up a regulated software org.

---

## Founder & background
Raphaëlle Taub is CEO & co-founder of Matricis.ai. She is a normalienne (ENS Lyon) with a PhD in physics (Paris-Saclay) and an MBA from Collège des Ingénieurs — but crucially her first professional role was in **reinsurance risk analysis** ([JFD](https://www.joinjfd.com/en/raphaelle-taub-founder-of-matricis-ai-revolutionizing-female-radiology-through-ai/)), an insurance-sector background that tops the priority axis.
She co-founded the company with Élise Mekkaoui (an endometriosis patient who originated the concept) and Arnaud (an ML post-doc), spun out of AP-HP and INRIA. CEO role confirmed via her [LinkedIn](https://www.linkedin.com/in/raphaelle-taub-370382b9).

## Funding & momentum
Founded 2022 ([Crunchbase](https://www.crunchbase.com/organization/matricis-ai)); won the **i-Lab 2024** national deeptech grant ([data.gouv.fr](https://www.data.gouv.fr/datasets/laureats-i-lab-concours-national-daide-a-la-creation-dentreprises-de-technologies-innovantes-1)).
Backed by the **Allianz France accelerator** (Fall Batch 2024), Station F, 212Founders, Next Sequence and Prevent2Care Lab. No confirmed priced round found — profile fits seed/grant-funded with a raise likely ahead to fund CE marking, clinical validation and US growth. Major momentum signal: **first US clinical pilot launched April 2026 with SimonMed Imaging** ([Yahoo Finance](https://finance.yahoo.com/sectors/healthcare/articles/matricis-ai-launches-first-u-182900635.html), [SimonMed](https://simonmed.com/about/news/simonmed-matricis-ai-mri-endometriosis-detection/)).

## Product & regulatory
**EndomAI** is an AI copilot that reads pelvic MRI to detect, map and characterize endometriosis (and adenomyosis/fibroids), producing standardized reports and surgical-planning lesion maps; reads stay radiologist-supervised ([Yahoo Finance](https://finance.yahoo.com/sectors/healthcare/articles/matricis-ai-launches-first-u-182900635.html)).
Taub describes it as a **"class 2.a medical device, subject to strict European standards"** with planned **reimbursement** by Social Security/insurers, requiring formal clinical studies ([JFD](https://www.joinjfd.com/en/raphaelle-taub-founder-of-matricis-ai-revolutionizing-female-radiology-through-ai/)) — i.e. a clear MDR/CE + IEC 62304 + reimbursement trigger, now compounded by a US/FDA path.

## Pain & buying signals
A lean ENS/INRIA deeptech team is carrying a class IIa SaMD through CE marking, clinical validation and now a 200-patient US pilot — heavy regulated-software lifecycle work with no evidence of a dedicated CTO/regulatory-engineering function (Arnaud's ML post-doc covers research, not production medical-software traceability).
Reachable: named CEO with active LinkedIn and a **published company email** (`contact@matricis.ai`, per the press release).

**Why OmDev fits:** OmDev gives Matricis a senior dev team + dedicated CTO + a compliance engine (per-build signed SOUP register, requirements-to-code-to-test traceability feeding the IEC 62304/MDR file) at a fixed monthly price ~3x cheaper than building that regulated-software org in-house — with Matricis owning the code, freeing the founders' ML talent for the model and the dual CE/US filings.

---
**Sources:** https://www.joinjfd.com/en/raphaelle-taub-founder-of-matricis-ai-revolutionizing-female-radiology-through-ai/ · https://matricis.ai/ · https://finance.yahoo.com/sectors/healthcare/articles/matricis-ai-launches-first-u-182900635.html · https://simonmed.com/about/news/simonmed-matricis-ai-mri-endometriosis-detection/ · https://www.crunchbase.com/organization/matricis-ai · https://app.dealroom.co/companies/matricis_ai · https://www.data.gouv.fr/datasets/laureats-i-lab-concours-national-daide-a-la-creation-dentreprises-de-technologies-innovantes-1 · https://www.myfrenchstartup.com/fr/startup-france/344760/matricisai · https://www.linkedin.com/in/raphaelle-taub-370382b9